HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy.

Nat Commun · 2025 · PMC12586486 · PMID 41188218

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

Although the interaction p-value for OS in RESPECT was nominally significant, these analyses were exploratory, based on small subgroups, and should be interpreted with caution.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.